Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis

Abstract

Diflunisal-mediated kinetic stabilization of TTR should ameliorate TTR amyloidoses, provided that the nonsteroidal anti-inflammatory drug liabilities can be managed clinically.